130 -6 (80) 2025 - Rajabova Z.R., Makhmudova L.I. - LIVER BIOMARKER DETECTION METHOD IN PREDICTING CHRONIC HEART FAILURE

LIVER BIOMARKER DETECTION METHOD IN PREDICTING CHRONIC HEART FAILURE

Rajabova Z.R. - Bukhara State Medical Institute named after Abu Ali ibn Sina

Makhmudova L.I. - Bukhara State Medical Institute named after Abu Ali ibn Sina

Resume

This article evaluated the Diagnostic and prognostic importance of liver biomarkers in patients with chronic heart failure (Sue). Transaminases (ALT, AST), bilirubin, γ-glutamyltransferase, and albumin levels were analyzed by comparison in the patient group according to sue levels. It has been found that impaired liver function, caused by persistent hypoperfusion and venous congestion, is associated with severe heart failure. Liver biomarkers can serve as an additional prognostic tool in assessing the risk of developing Sue. The results obtained confirm that the inclusion of liver biomarkers in risk stratification and treatment individualization algorithms is of clinical importance

Key words: chronic heart failure, liver biomarkers, prognostic markers, ALT, AST, bilirubin, hepatic hypoperfusion, liver dysfunction, prognosis, risk stratification

First page

657

Last page

662

For citation:Rajabova Z.R., Makhmudova L.I. - LIVER BIOMARKER DETECTION METHOD IN PREDICTING CHRONIC HEART FAILURE//New Day in Medicine 6(80)2025 657-662 https://newdayworldmedicine.com/en/new_day_medicine/6-80-2025

List of References

  1. McDonagh T.A. et al. 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur Heart J. 2021;42(36):3599–3726.
  2. Zannad F. et al. Heart failure with reduced ejection fraction: current understanding and emerging therapies. Lancet. 2022;400(10360):51–67.
  3. Nikolaou M. et al. Liver dysfunction in heart failure: prevalence, pathophysiology, and clinical significance. J Am Coll Cardiol. 2020;75(10):1074–1084.
  4. Kociol R.D. et al. Ghepato-cardiorenal syndrome: the interplay of heart, kidney, and liver in advanced heart failure. Heart Fail Clin. 2022;18(3):277–291.
  5. Samsky M.D. et al. Liver function tests in patients with acute decompensated heart failure. J Am Coll Cardiol. 2013;61(24):2549–2560.
  6. Allen L.A. et al. Abnormal liver function tests in patients with heart failure: relationship to clinical variables and outcomes in the HF-ACTION study. J Card Fail. 2010;16(10): 888–895.
  7. Van Deursen V.M. et al. Prognostic value of liver function tests in heart failure patients: results from BIOSTAT-CHF study. Eur J Heart Fail. 2016;18(7):830–839.
  8. Бакиров Н.М., Халилов Ш.Б. Диагностическое и прогностическое значение печеночных ферментов при ХСН. Кардиология в Узбекистане. 2021;(2):22–26.
  9. Арипов Р.Ж., Юнусов Ж.Р. Хроническая сердечная недостаточность и печень: новые данные о взаимосвязи. Журнал клинической и экспериментальной. 2022;(1):45–49.

    file

    download